William A Werbel Selected Research

COVID-19

4/2024	COVID-19 vaccination induces distinct T-cell responses in pediatric solid organ transplant recipients and immunocompetent children.
2/2024	Anti-spike antibody durability after SARS-CoV-2 vaccination in adolescent solid organ transplant recipients.
1/2023	Low Omicron BA.4 and BA.5 neutralising activity and breakthrough COVID-19 following pre-exposure prophylaxis with tixagevimab plus cilgavimab in vaccinated patients with autoimmune disease.
1/2023	Your Outpatient has Coronavirus Disease 2019: What Are the Treatment Options in the Current Severe Acute Respiratory Syndrome Coronavirus 2 Variant Climate?
1/2023	Patient-reported outcomes after Tixagevimab and Cilgavimab pre-exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk.
1/2023	Persistent SARS-CoV-2-specific immune defects in kidney transplant recipients following third mRNA vaccine dose.
1/2023	Heterologous versus homologous boosting elicits qualitatively distinct, BA.5-cross-reactive T cells in transplant recipients.
1/2022	Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination.
1/2022	SARS-CoV-2 antibody testing for transplant recipients: A tool to personalize protection versus COVID-19.
1/2022	Higher Proinflammatory Cytokines Are Associated With Increased Antibody Titer After a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William A Werbel Research Topics

Disease

21	COVID-19 04/2024 - 01/2020
6	Infections 02/2024 - 10/2019
6	Musculoskeletal Diseases (Musculoskeletal Disease) 04/2022 - 01/2021
3	Breakthrough Infections 02/2024 - 10/2021
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 08/2023 - 01/2022
2	Coinfection 01/2022 - 01/2019
1	Fibrosis (Cirrhosis) 04/2023
1	Autoimmune Diseases (Autoimmune Disease) 01/2023
1	Necrosis 01/2022
1	Acute Kidney Injury (Acute Renal Failure) 01/2022
1	Multiple Myeloma 12/2021
1	Rheumatic Diseases (Rheumatism) 11/2021
1	Pain (Aches) 10/2021
1	Severe Acute Respiratory Syndrome 07/2021
1	Hepatitis 01/2021

Drug/Important Bio-Agent (IBA)

12	Messenger RNA (mRNA)IBA 04/2024 - 01/2021
7	mRNA VaccinesIBA 04/2024 - 01/2021
6	VaccinesIBA 04/2024 - 07/2021
3	COVID-19 VaccinesIBA 01/2022 - 10/2021
2	Immunoglobulin G (IgG)IBA 04/2024 - 01/2022
2	Antiviral Agents (Antivirals)IBA 01/2023 - 01/2019
2	remdesivirIBA 01/2023 - 01/2022
2	tixagevimabIBA 01/2023 - 01/2023
2	cilgavimabIBA 01/2023 - 01/2023
2	Monoclonal AntibodiesIBA 01/2023 - 01/2023
1	Combined VaccinesIBA 04/2024
1	molnupiravirIBA 01/2023
1	Complement System Proteins (Complement)IBA 01/2023
1	Ad26COVS1IBA 01/2023
1	nirmatrelvir and ritonavir drug combinationIBA 01/2023
1	insulin receptor-related receptor (IRR)IBA 01/2022
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022
1	AntibodiesIBA 01/2022
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2021
1	Basiliximab FDA Link 01/2021
1	dicarboxydine (DCD)IBA 11/2020
1	SuspensionsIBA 01/2020
1	liposomal amphotericin B FDA Link 10/2019
1	Voriconazole (Vfend)FDA LinkGeneric 10/2019

Therapy/Procedure

4	Kidney Transplantation 01/2021 - 01/2020
4	Transplantation 12/2020 - 01/2020
3	Therapeutics 01/2023 - 01/2022
2	Organ Transplantation 10/2022 - 01/2020
2	Liver Transplantation 01/2021 - 01/2021
1	Immunomodulation 01/2022